Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
Tesamorelin / Ipamorelin
Batch #
N/A
Formula
C221H366N72O67S
Mol Wt
5136 g/mol
CAS
218949-48-5
latest
ISO 17025
8× Testing
99.7%
Purity
VariantTesamorelin / Ipamorelin
COA ##13142
LabeledTesamorelin 12 mg / Ipamorelin 2 mg
Validation KeyAXISBIOTECH
Tested05/12/26
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.7%
✓
Net Peptide Content - Tesamorelin 12 mg / Ipamorelin 2 mg
✓
Identity (HPLC) - Tesamorelin / Ipamorelin
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >99%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
Effects of growth hormone-releasing factor on abdominal fat in HIV-infected patients with fat accumulation
02
Ipamorelin, the first selective growth hormone secretagogue
03
Growth hormone secretagogues: history, mechanism of action, and clinical development
04
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295
05
Synergistic effect of combined administration of GHRH and GHRP on GH secretion
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
